BDNF Val66Met and childhood adversity on response to physical exercise and internet-based cognitive behavioural therapy in depressed Swedish adults

Journal of Psychiatric Research

Volumn 93, Issue , 2017, Pages 50-58

  Rahman, Md Shafiqur ^a   Millischer, Vincent ^a,b   Zeebari, Zangin ^a   Forsell, Yvonne ^a   Lavebratt, Catharina ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Childhood adversity; Cognitive therapy; Depression; Exercise; Gene environment interactions; Neurotrophic factor

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; METHIONINE; VALINE;

ADULT; ALLELE; ARTICLE; CHILDHOOD DISEASE; COGNITIVE BEHAVIORAL THERAPY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; EXERCISE; FEMALE; FOLLOW UP; GENOTYPE; HOMOZYGOTE; HUMAN; INTERNET; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SWEDISH CITIZEN; TREATMENT RESPONSE; ADOLESCENT; CHILD ABUSE; COGNITIVE THERAPY; EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PHYSIOLOGY; PROCEDURES; PSYCHOLOGY; STATISTICAL MODEL; SWEDEN;

ADOLESCENT; ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHILD ABUSE; COGNITIVE THERAPY; COHORT STUDIES; DEPRESSION; EXERCISE; FEMALE; GENOTYPE; HUMANS; INTERNET; LOGISTIC MODELS; MALE; METHIONINE; MIDDLE AGED; POLYMORPHISM, GENETIC; STATISTICS, NONPARAMETRIC; SWEDEN; VALINE;

EID: 85020001135     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2017.05.007     Document Type: Article

References (54)

1. Barker, P.A., Whither proBDNF?. Nat. Neurosci. 12 (2009), 105–106, 10.1038/nn0209-105.
2. Bonaccorso, S., Sodhi, M., Li, J., Bobo, W.V., Chen, Y., Tumuklu, M., Theleritis, C., Jayathilake, K., Meltzer, H.Y., The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia. Bipolar Disord. 17 (2015), 528–535, 10.1111/bdi.12294.
3. Bukh, J.D., Bock, C., Vinberg, M., Werge, T., Gether, U., Kessing, L.V., No interactions between genetic polymorphisms and stressful life events on outcome of antidepressant treatment. Eur. Neuropsychopharmacol. 20 (2010), 327–335, 10.1016/j.euroneuro.2009.11.004.
4. Chi, M.H., Chang, H.H., Lee, S.-Y., Lee, I.H., Gean, P.W., Yang, Y.K., Lu, R.-B., Chen, P.S., Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. J. Affect. Disord. 126 (2010), 430–435, 10.1016/j.jad.2010.07.006.
5. Colle, R., Deflesselle, E., Martin, S., David, D.J., Hardy, P., Taranu, A., Falissard, B., Verstuyft, C., Corruble, E., BDNF/TRKB/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients. Pharmacogenomics 16 (2015), 997–1013, 10.2217/pgs.15.56.
6. Colle, R., Gressier, F., Verstuyft, C., Deflesselle, E., Lépine, J.-P., Ferreri, F., Hardy, P., Guilloux, J.-P., Petit, A.-C., Fève, B., Falissard, B., Becquemont, L., Corruble, E., Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients. J. Affect. Disord. 175 (2015), 233–240, 10.1016/j.jad.2015.01.013.
7. DEPRESSION: A Global Crisis, 2012.
8. Egan, M.F., Kojima, M., Callicott, J.H., Goldberg, T.E., Kolachana, B.S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., Lu, B., Weinberger, D.R., The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112 (2003), 257–269, 10.1016/S0092-8674(03)00035-7.
9. Felmingham, K.L., Dobson-Stone, C., Schofield, P.R., Quirk, G.J., Bryant, R.A., The brain-derived neurotrophic factor Val66Met polymorphism predicts response to exposure therapy in posttraumatic stress disorder. Biol. Psychiatry 73 (2013), 1059–1063, 10.1016/j.biopsych.2012.10.033.
10. Garza, A.A., Ha, T.G., Garcia, C., Chen, M.J., Russo-Neustadt, A.A., Exercise, antidepressant treatment, and BDNF mRNA expression in the aging brain. Pharmacol. Biochem. Behav. 77 (2004), 209–220, 10.1016/j.pbb.2003.10.020.
11. Groves, J.O., Is it time to reassess the BDNF hypothesis of depression?. Mol. Psychiatry 12 (2007), 1079–1088, 10.1038/sj.mp.4002075.
12. Gujral, S., Manuck, S.B., Ferrell, R.E., Flory, J.D., Erickson, K.I., The BDNF Val66Met polymorphism does not moderate the effect of self-reported physical activity on depressive symptoms in midlife. Psychiatry Res. 218 (2014), 93–97, 10.1016/j.psychres.2014.03.028.
13. Hallgren, M., Kraepelien, M., Ojehagen, A., Lindefors, N., Zeebari, Z., Kaldo, V., Forsell, Y., Physical exercise and internet-based cognitive-behavioural therapy in the treatment of depression: randomised controlled trial. Br. J. Psychiatry 207 (2015), 227–234, 10.1192/bjp.bp.114.160101.
14. Jamal, M., Van Der Does, W., Penninx, B.W.J.H., Effect of variation in BDNF Val 66 Met polymorphism, smoking, and nicotine dependence on symptom severity of depressive and anxiety disorders. Drug Alcohol Depend. 148 (2015), 150–157, 10.1016/j.drugalcdep.2014.12.032.
15. Joe, K.-H., Kim, Y.-K., Kim, T.-S., Roh, S.-W., Choi, S.-W., Kim, Y.-B., Lee, H.-J., Kim, D.-J., Decreased plasma brain-derived neurotrophic factor levels in patients with alcohol dependence. Alcohol. Clin. Exp. Res. 31 (2007), 1833–1838, 10.1111/j.1530-0277.2007.00507.x.
16. Kaufman, J., Yang, B.-Z., Douglas-Palumberi, H., Houshyar, S., Lipschitz, D., Krystal, J.H., Gelernter, J., Social supports and serotonin transporter gene moderate depression in maltreated children. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 17316–17321, 10.1073/pnas.0404376101.
17. Keers, R., Will gene–environment interactions explain differential antidepressant response?. Per. Med. 9 (2012), 319–322, 10.2217/pme.12.28.
18. Keers, R., Uher, R., Gene-environment interaction in major depression and antidepressant treatment response. Curr. Psychiatry Rep. 14 (2012), 129–137, 10.1007/s11920-011-0251-x.
19. Klengel, T., Binder, E.B., Gene × environment interactions in the prediction of response to antidepressant treatment. Int. J. Neuropsychopharmacol. 16 (2013), 701–711, 10.1017/S1461145712001459.
20. Knaepen, K., Goekint, M., Heyman, E.M., Meeusen, R., Neuroplasticity - exercise-induced response of peripheral brain-derived neurotrophic factor: a systematic review of experimental studies in human subjects. Sports Med. 40 (2010), 765–801, 10.2165/11534530-000000000-00000.
21. Kovacs, D., Gonda, X., Petschner, P., Edes, A., Eszlari, N., Bagdy, G., Juhasz, G., Antidepressant treatment response is modulated by genetic and environmental factors and their interactions. Ann. Gen. Psychiatry 13 (2014), 1–9, 10.1186/1744-859X-13-17.
22. Laje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N., Kelmendi, B., Simen, A., McMahon, F.J., Sanacora, G., Zarate, C., Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol. Psychiatry, 2012, 10.1016/j.biopsych.2012.05.031.
23. Lang, U.E., Hellweg, R., Sander, T., Gallinat, J., The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations. Mol. Psychiatry 14 (2009), 120–122, 10.1038/mp.2008.80.
24. Lavebratt, C., Åberg, E., Sjöholm, L.K., Forsell, Y., Variations in FKBP5 and BDNF genes are suggestively associated with depression in a Swedish population-based cohort. J. Affect. Disord. 125 (2010), 249–255, 10.1016/j.jad.2010.02.113.
25. Lee, B.H., Kim, Y.K., The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig. 7 (2010), 231–235, 10.4306/pi.2010.7.4.231.
26. Lester, K.J., Hudson, J.L., Tropeano, M., Creswell, C., Collier, D.A., Farmer, A., Lyneham, H.J., Rapee, R.M., Eley, T.C., Neurotrophic gene polymorphisms and response to psychological therapy. Transl. Psychiatry, 2, 2012, e108, 10.1038/tp.2012.33.
27. Levine, M.E., Crimmins, E.M., Prescott, C.A., Phillips, D., Arpawong, T.E., Lee, J., A polygenic risk score associated with measures of depressive symptoms among older adults. Biodemogr. Soc. Biol. 60 (2014), 199–211, 10.1080/19485565.2014.952705.
28. Lipsky, R.H., Marini, A.M., Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity. Ann. N. Y. Acad. Sci. 1122 (2007), 130–143, 10.1196/annals.1403.009.
29. Liu, J.J., Lou, F., Lavebratt, C., Forsell, Y., Impact of childhood adversity and Vasopressin receptor 1a variation on social interaction in adulthood: a cross-sectional study. PLoS One, 10, 2015, e0136436, 10.1371/journal.pone.0136436.
30. Mata, J., Thompson, R.J., Gotlib, I.H., BDNF genotype moderates the relation between physical activity and depressive symptoms. Health Psychol. 29 (2010), 130–133, 10.1037/a0017261.
31. Menke, A., Binder, E.B., Epigenetic alterations in depression and antidepressant treatment. Dialogues Clin. Neurosci. 16 (2014), 395–404.
32. Moreira, F.P., Fabião, J.D., Bittencourt, G., Wiener, C.D., Jansen, K., Oses, J.P., de Á, Quevedo, L., Souza, L.D.M., Crispim, D., Portela, L.V., Pinheiro, R.T., Lara, D.R., Kaster, M.P., da Silva, R.A., Ghisleni, G., The Met allele of BDNF Val66Met polymorphism is associated with increased BDNF levels in generalized anxiety disorder. Psychiatr. Genet. 25 (2015), 201–207, 10.1097/YPG.0000000000000097.
33. Musil, R., Peter Zill, B., Florian Seemü ller, B., Brigitta Bondy, B., Michael Obermeier, B., Ilja Spellmann, B., Wolfram Bender, B., Mazda Adli, B., Isabella Heuser, B., Joachim Zeiler, B., Wolfgang Gaebel, B., Wolfgang Maier, B., Marcella Rietschel, B., Dan Rujescu, B., Rebecca Schennach, B., Hans-Jü rgen Möller, B., Michael Riedel, B., Musil, R., Zill, Á.F., Seemüller, Á.B., Bondy, Á.M., Obermeier, Á.I., Spellmann, Á.D., Rujescu, Á.R., Schennach, Á.H.-J., Möller, Á.M., Riedel, Á.P., Bender, W., Adli, M., Heuser, I., Zeiler, J., Gaebel, W., Maier, W., Rietschel, M., Riedel, M., No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. Eur. Arch. Psychiatry Clin. Neurosci. 263 (2013), 405–412, 10.1007/s00406-012-0364-1.
34. Nanni, V., Uher, R., Danese, A., Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. Am. J. Psychiatry 169 (2012), 141–151, 10.1176/appi.ajp.2011.11020335.
35. Nestler, E.J., Barrot, M., DiLeone, R.J., Eisch, A.J., Gold, S.J., Monteggia, L.M., Neurobiology of depression. Neuron 34 (2002), 13–25, 10.1016/S0896-6273(02)00653-0.
36. Nierenberg, A.A., DeCecco, L.M., Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J. Clin. Psychiatry 62 (2001), 5–9.
37. Notaras, M., Hill, R., van den Buuse, M., The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy. Mol. Psychiatry 20 (2015), 916–930, 10.1038/mp.2015.27.
38. Russo-Neustadt, A., Chen, M., Brain-derived neurotrophic factor and antidepressant activity. Curr. Pharm. Des. 11 (2005), 1495–1510, 10.2174/1381612053764788.
39. Sakata, K., Brain-derived neurotrophic factor for depression therapeutics. Austin J. Pharmacol. Ther. 2 (2014), 1–10.
40. Saunders, J.B., Aasland, O.G., Babor, T.F., de la Fuente, J.R., Grant, M., Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption–II. Addiction 88 (1993), 791–804.
41. Sen, S., Nesse, R.M., Stoltenberg, S.F., Li, S., Gleiberman, L., Chakravarti, A., Weder, A.B., Burmeister, M., A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology 28 (2003), 397–401, 10.1038/sj.npp.1300053.
42. Snaith, R.P., Harrop, F.M., Newby, D.A., Teale, C., Grades scores of the montegomery - Asberg depression and the clinical anxiety scales. Br. J. Psychiatry 148 (1986), 599–601, 10.1192/bjp.148.5.599.
43. Stavrakakis, N., Oldehinkel, A.J., Nederhof, E., Oude Voshaar, R.C., Verhulst, F.C., Ormel, J., de Jonge, P., Plasticity genes do not modify associations between physical activity and depressive symptoms. Heal. Psychol. 32 (2013), 785–792, 10.1037/a0030111.
44. Sullivan, P.F., Neale, M.C., Kendler, K.S., Genetic epidemiology of major depression: review and meta-analysis. Am. J. Psychiatry 157 (2000), 1552–1562, 10.1176/appi.ajp.157.10.1552.
45. Szyf, M., The early life environment and the epigenome. Biochim. Biophys. Acta 1790 (2009), 878–885, 10.1016/j.bbagen.2009.01.009.
46. Taylor, W.D., Züchner, S., McQuoid, D.R., Steffens, D.C., Blazer, D.G., Krishnan, K.R.R., Social support in older individuals: the role of the BDNF Val66Met polymorphism. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 147B (2008), 1205–1212, 10.1002/ajmg.b.30754.
47. Toups, M.S.P., Greer, T.L., Kurian, B.T., Grannemann, B.D., Carmody, T.J., Huebinger, R., Rethorst, C., Trivedi, M.H., Effects of serum Brain Derived Neurotrophic Factor on exercise augmentation treatment of depression. J. Psychiatr. Res. 45 (2011), 1301–1306, 10.1016/j.jpsychires.2011.05.002.
48. Tsai, S.-J., Hong, C.-J., Liou, Y.-J., Effects of BDNF polymorphisms on antidepressant action. Psychiatry Investig. 7 (2010), 236–242, 10.4306/pi.2010.7.4.236.
49. Undén, A.-L., Orth-Gomér, K., Development of a social support instrument for use in population surveys. Soc. Sci. Med. 29 (1989), 1387–1392, 10.1016/0277-9536(89)90240-2.
50. Verhagen, M., van der Meij, A., van Deurzen, P.A.M., Janzing, J.G.E., Arias-Vásquez, A., Buitelaar, J.K., Franke, B., Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol. Psychiatry 15 (2010), 260–271, 10.1038/mp.2008.109.
51. Yoshida, T., Ishikawa, M., Niitsu, T., Nakazato, M., Watanabe, H., Shiraishi, T., Shiina, A., Hashimoto, T., Kanahara, N., Hasegawa, T., Enohara, M., Kimura, A., Iyo, M., Hashimoto, K., Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One, 7, 2012, e42676, 10.1371/journal.pone.0042676.
52. Zhang, J., Geula, C., Lu, C., Koziel, H., Hatcher, L.M., Roisen, F.J., Neurotrophins regulate proliferation and survival of two microglial cell lines in vitro. Exp. Neurol. 183 (2003), 469–481.
53. Zhou, L., Xiong, J., Lim, Y., Ruan, Y., Huang, C., Zhu, Y., Zhong, J., Xiao, Z., Zhou, X.-F., Upregulation of blood proBDNF and its receptors in major depression. J. Affect. Disord. 150 (2013), 776–784, 10.1016/j.jad.2013.03.002.
54. Zou, Y.-F., Ye, D.-Q., Feng, X.-L., Su, H., Pan, F.-M., Liao, F.-F., Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur. Neuropsychopharmacol. 20 (2010), 535–544, 10.1016/j.euroneuro.2009.12.005.